Literature DB >> 10667416

The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens.

V Costes1, V Magen, E Legouffe, L Durand, P Baldet, J F Rossi, B Klein, J Brochier.   

Abstract

Plasmocyte selective monoclonal antibodies (MAb) recognizing syndecan-1 have recently been described. They belong to a new cluster, CD138. Using the MAb MI15, we investigated the expression of syndecan-1 in routinely paraffin-embedded tissues. Nontumoral lymph nodes (25 cases) and bone marrow biopsy specimens (63 cases) showed strong membrane staining of plasma cells only, allowing accurate analysis of the nuclear structure. The MI15 positivity correlated with kappa and lambda light chain expression in the cytoplasm. The percentages of plasma cells calculated in bone marrow biopsy specimens after MI15 staining were, respectively, 2.1% (range, 1% to 4%) in normal bone marrows, 8.5% (range, 5 to 17) in reactive plasmocytosis, and 4.66% in monoclonal gammapathy of undetermined significance (MGUS) patients (range, 1 to 13), in the same range but slightly higher than those obtained on smears or on hematoxylin and eosin (H&E)-stained sections. In multiple myeloma (40 cases), all plasma cell types were marked, and Mi15 MAb gave additional information in 8 of 40 (20%) patients. In lymph nodes, Mi15 MAb reacted with Reed-Sternberg cells of classical Hodgkin's disease in 23 of 31 cases (74%) with variable intensity. In contrast, nodular lymphocyte predominance Hodgkin's disease (10 cases), most B cell lymphomas (88 of 107 cases) and all T cell lymphomas (30 cases) were negative. In B cell lymphomas, plasmocytomas (8 cases), plasmocytic lymphomas (2 cases), and 5 of 13 cases of immunoblastic lymphoma with plasmocytoid differentiation were stained. In lymphoplasmocytoid lymphomas (4 lymph nodes and 20 bone marrow biopsy specimens), only mature plasma cells were positive. Moreover, a wide distribution of syndecan-1 was observed in normal and tumoral epithelial tissues. Finally, Mi15 MAb appears to be a reliable marker for identifying and quantifying normal and tumoral plasma cells in paraffin-embedded bone marrow and lymph node samples.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10667416     DOI: 10.1016/s0046-8177(99)90160-0

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  24 in total

Review 1.  Microarray-based understanding of normal and malignant plasma cells.

Authors:  John De Vos; Dirk Hose; Thierry Rème; Karin Tarte; Jérôme Moreaux; Karéne Mahtouk; Michel Jourdan; Hartmut Goldschmidt; Jean-François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Immunol Rev       Date:  2006-04       Impact factor: 12.988

2.  Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.

Authors:  Samer Z Al-Quran; Lijun Yang; James M Magill; Raul C Braylan; Vonda K Douglas-Nikitin
Journal:  Hum Pathol       Date:  2007-08-21       Impact factor: 3.466

3.  Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells.

Authors:  Anouk Caraux; Bernard Klein; Bruno Paiva; Caroline Bret; Alexander Schmitz; Gwenny M Fuhler; Nico A Bos; Hans E Johnsen; Alberto Orfao; Martin Perez-Andres
Journal:  Haematologica       Date:  2010-01-15       Impact factor: 9.941

4.  Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma.

Authors:  K Mahtouk; F W Cremer; T Rème; M Jourdan; M Baudard; J Moreaux; G Requirand; G Fiol; J De Vos; M Moos; P Quittet; H Goldschmidt; J-F Rossi; D Hose; B Klein
Journal:  Oncogene       Date:  2006-05-29       Impact factor: 9.867

Review 5.  Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.

Authors:  Rajendra Gharbaran
Journal:  Tumour Biol       Date:  2016-06-18

6.  Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.

Authors:  Weixin Wang; Meghan Corrigan-Cummins; Emily A Barber; Layla M Saleh; Adriana Zingone; Azam Ghafoor; Rene Costello; Yong Zhang; Roger J Kurlander; Neha Korde; Aldo M Roccaro; Irene M Ghobrial; Ola Landgren; Katherine R Calvo
Journal:  J Mol Diagn       Date:  2015-09-30       Impact factor: 5.568

7.  Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients.

Authors:  P Quittet; P Ceballos; E Lopez; Z Y Lu; P Latry; C Becht; E Legouffe; N Fegueux; C Exbrayat; D Pouessel; V Rouillé; J P Daures; B Klein; J F Rossi
Journal:  Bone Marrow Transplant       Date:  2006-08       Impact factor: 5.483

8.  Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells.

Authors:  Caroline Bret; Dirk Hose; Thierry Reme; Anne-Catherine Sprynski; Karène Mahtouk; Jean-François Schved; Philippe Quittet; Jean-François Rossi; Hartmut Goldschmidt; Bernard Klein
Journal:  Br J Haematol       Date:  2009-03-02       Impact factor: 6.998

9.  Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma.

Authors:  Sanja Stifter; Emina Babarović; Toni Valković; Irena Seili-Bekafigo; Christophe Stemberger; Antica Nacinović; Ksenija Lucin; Nives Jonjić
Journal:  Diagn Pathol       Date:  2010-05-18       Impact factor: 2.644

10.  Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study.

Authors:  Ji Myung Kim; Jung Ae Lee; In Sung Cho; Chun Hwa Ihm
Journal:  Korean J Hematol       Date:  2010-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.